Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

导出 OA

翻译打印收藏纠错

作者： Padmanee,Sharma ^[1] ; Arlene,Siefker-Radtke ^[1] ; Filippo,de Braud ^[2] ; Umberto,Basso ^[3] ; Emiliano,Calvo ^[4] ; Petri,Bono ^[5] ; Michael A,Morse ^[6] ; Paolo A,Ascierto ^[7] ; Jose,Lopez-Martin ^[8] ; Peter,Brossart ^[9] ; Kristoffer,Rohrberg ^[10] ; Begoña,Mellado ^[11] ; Bruce S,Fischer ^[12] ; Stephanie,Meadows-Shropshire ^[13] ; Abdel Saci ^[13] ; Margaret K,Callahan ^[13] ; Jonathan,Rosenberg ^[14]

作者单位： 1 The University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] 2 Istituto Nazionale dei Tumori, Milan, Italy. ^[2] 3 Istituto Oncologico Veneto-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy. ^[3] 4 START Madrid-Centro Integral Oncológico Clara Campal, Madrid, Spain. ^[4] 5 Helsinki University Hospital, Helsinki, Finland. ^[5] 6 University of Helsinki, Helsinki, Finland. ^[6] 7 Duke University Medical Center, Durham, NC. ^[7] 8 Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione G. Pascale, Naples, Italy. ^[8] 9 Hospital Universitario 12 de Octubre, Madrid, Spain. ^[9] 10 University Hospital of Bonn, Bonn, Germany. ^[10] 11 Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark. ^[11] 12 Hospital Clinic of Barcelona, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. ^[12] 13 Bristol-Myers Squibb, Princeton, NJ. ^[13] 14 Memorial Sloan Kettering Cancer Center, New York, NY. ^[14] 15 Weill Cornell Medical College, New York, NY. ^[15]